Key takeaways
Tirzepatide (Zepbound) and liraglutide (Victoza) are both injectable medications used to manage certain health conditions. They belong to the class of medications known as glucagon-like peptide-1 (GLP-1) agonists, which help control blood sugar levels and appetite. While both medications can aid in weight management, Zepbound is FDA-approved for weight loss and sleep apnea, whereas Victoza is approved for Type 2 diabetes and reducing heart-related risks in adults with diabetes. Zepbound is taken once a week, while Victoza is taken daily. Zepbound is a glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist, while Victoza is solely a GLP-1 receptor agonist. Common side effects for both medications include nausea and diarrhea. Both medications carry a risk of thyroid cancer and pancreatitis, and they have similar interactions, which can include other diabetes medications, warfarin (Jantoven, Coumadin), and birth control pills. Zepbound is available only as a brand-name medication, while Victoza has a lower-cost generic available.
